NCT04166474View on ClinicalTrials.gov

Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

February 7, 2024

Study Completion Date

February 7, 2024

Conditions
HivTuberculosis
Interventions
DRUG

Dolutegravir

Dosed at 50 mg bd on 3 separate occasions with low, medium and high doses of rifampicin. Dosed at 50 mg od without rifampicin.

Trial Locations (2)

Unknown

Desmond Tutu Health Foundation, Cape Town

Infectious Diseases Institute, Kampala

All Listed Sponsors
collaborator

Infectious Disease Institute, Kampala, Uganda

OTHER

collaborator

Desmond Tutu HIV Centre

OTHER

lead

Helen Reynolds

OTHER

NCT04166474 - Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin | Biotech Hunter | Biotech Hunter